Trial Profile
NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; CST 101 (Primary) ; Cyclophosphamide (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUILT-3.052
- Sponsors ImmunityBio
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
- 02 Jun 2017 New trial record